AMISULPRIDE SHOULD NOT BE GIVEN WITH DRUGS THAT MAY INDUCE ARRHYTHMIAS (INCLUDING TORSADE DE POINTES); SUCH DRUGS INCLUDE SOME ANTIARRHYTHMICS, CISAPRIDE, THIORIDAZINE, ERYTHROMYCIN, AND HALOFANTRINE. THE RISK OF ARRHYTHMIAS IS ALSO INCREASED WITH DRUGS THAT PROLONG THE QT INTERVAL, SUCH AS PIMOZIDE, HALOPERIDOL, AND TRICYCLIC ANTIDEPRESSANTS, AND WITH DRUGS THAT PRODUCE BRADYCARDIA OR HYPOKALAEMIA, INCLUDING BETA BLOCKERS, SOME CALCIUM-CHANNEL BLOCKERS, CLONIDINE, DIGOXIN, GUANFACINE, POTASSIUM-DEPLETING DIURETICS, AND LITHIUM; USE OF THESE DRUGS WITH AMISULPRIDE REQUIRES CAUTION.
THE CENTRAL EFFECTS OF OTHER CNS DEPRESSANTS INCLUDING ALCOHOL MAY BE ENHANCED BY AMISULPRIDE. AMISULPRIDE MAY ALSO ENHANCE THE EFFECTS OF ANTIHYPERTENSIVE DRUGS. THE DOPAMINE-BLOCKING ACTIVITY OF AMISULPRIDE MAY ANTAGONISE THE ACTIONS OF DOPAMINERGICS SUCH AS LEVODOPA AND THEY SHOULD NOT BE GIVEN TOGETHER.
IN 7 PATIENTS RECEIVING AMISULPRIDE, INTRODUCTION OF LITHIUM RESULTED IN AN AVERAGE INCREASE OF 32% OF THE DOSE-CORRECTED PLASMA CONCENTRATION OF AMISULPRIDE. AN EARLIER STUDY HAD NOTED THAT PLASMA CONCENTRATIONS OF AMISULPRIDE WERE RAISED IN PATIENTS ALSO TAKING CLOZAPINE.